Overview
- Shares rose 13.99% on Monday to close at $6.68 as traders bought the dip and positioned for the next catalyst.
- Based on prior reporting patterns, the company is expected to release third‑quarter financial and operating details in the first week of November.
- In the second quarter, net loss widened 76% year over year to $171.9 million, while revenue increased 33% to $19.2 million, largely from collaborations.
- Jim Cramer described the stock as a meme name and said he expects such buying to lift it, yet he reiterated that he needs to see proof of concept.
- Recursion is a clinical‑stage biotech that applies machine learning to drug discovery and counts Nvidia as an investor.